On 26 April 2011, the Supreme Court handed down an interesting decision en banc declaring that a Judge who had confirmed the validity of a patent while sitting on a Court of Appeal is not prevented from reconsidering the validity of the same patent while sitting on the Supreme Court. Ratiopharm had requested the removal of Justice F. because while he was the President of Chamber 15 of the Court of Appeal of Barcelona, his Chamber handed down a judgment on 12 June 2001 confirming the validity of two patents relating to amlodipine. Although Ratiopharm had not been a party in the previous case, this company argued that by having confirmed the validity of these patents in the previous case, Justice F. was prevented from re-considering the validity of the same patents while sitting on the Supreme Court. In its decision of 26 April 2011, the Supreme Court dismissed Ratiopharm’s challenge relying on case law from the European Court of Human Rights.


_____________________________

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.


Kluwer IP Law

The 2022 Future Ready Lawyer survey showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how Kluwer IP Law can support you.

Kluwer IP Law
This page as PDF